Abstract:Recent publications have reported that α-synuclein seed amplification assays (SAAs) have potential as biomarker tests for Parkinson disease (PD). This has led to several recommendations: to integrate α-synuclein SAA into care to facilitate an earlier diagnosis of PD 1 -3 ; to incorporate α-synuclein SAA testing into a research-based definition of neuronal α-synucleinopathy, encompassing a pathological process with clinical and preclinical phases 1 -3 ; and to use α-synuclein SAA to guide clinical trial enrollment. Although α-synuclein SAA is a promising tool, caution is needed in deploying α-synuclein SAA in general neurology practice. α-Synuclein SAAs rely on the seeding properties of abnormal α-synuclein in cerebrospinal fluid or other biological samples, including skin biopsies, and measure the kinetics of propagating α-synuclein aggregation. These assays have been developed using postmortem brain tissue, and a 2023 meta-analysis demonstrated that 88% of patients clinically diagnosed with PD have a positive α-synuclein SAA result. 4 However, the usefulness of this assay is influenced by limitations in the published literature and uncertainty in the early diagnosis of PD. The Queen Square Brain Bank (QSBB) clinical diagnostic criteria have been widely used to diagnose PD in clinical research studies and general neurology practice. The QSBB criteria were established by careful clinical documentation of patients who were followed up through their disease course and had pathologically defined PD with Lewy bodies and neurites at autopsy. 5 Although the criteria predated the description of α-synuclein as the major protein in Lewy bodies, they provided a firm clinical basis for α-synuclein–related PD. In sharp contrast, most of the recent articles on α-synuclein SAA have relied on a cross-sectional diagnosis of PD. Carefully conducted longitudinal clinical studies have shown that around 10% of patients diagnosed with PD at their initial neurological assessment have an alternative disorder, including conditions that are more benign (essential tremor, dystonic tremor, or normal aging) and more malignant (Parkinson plus syndromes, progressive supranuclear palsy [PSP], multiple system atrophy [MSA], or corticobasal syndrome). Because a clinical diagnosis of PD can be prone to error when made at a single time point, the QSBB criteria require observing symptoms over time (eg, persistent asymmetry) to make a diagnosis. Similar prospective criteria are included in the Movement Disorder Society's diagnostic criteria for PD, 6 which emphasize the need to observe patients over time to improve diagnostic certainty. The true diagnostic value of α-synuclein SAA cannot be established, therefore, without longitudinal follow-up and, ideally, postmortem examination of patients with both positive and negative α-synuclein SAA results. Many α-synuclein SAA studies have used healthy controls unaffected by neurodegenerative disease. However, the main clinical challenge is not in distinguishing PD from healthy controls but in differentiating PD from MSA, PSP, corticobasal syndrome, normal pressure hydrocephalus, and cerebrovascular disease. The potential cross-reactivity of the α-synuclein SAA across different neurodegenerative disease proteins needs to be established using cerebrospinal fluid samples and postmortem follow-up before α-synuclein SAA can be used in clinical practice. The specificity of α-synuclein SAA is much lower in distinguishing PD from MSA, compared with distinguishing PD from healthy controls. 4 There will also be many patients who have false-positive α-synuclein SAA results because of α-synuclein copathology, such as patients with Lewy body pathology and primary Alzheimer disease. The α-synuclein SAA will enable definition of the effects of copathology in large patient series of other clinically diagnosed neurodegenerative disorders. With respect to asymptomatic individuals, incidental Lewy body pathology occurs in 1 in 6 older adults, who die without any signs of PD. 5 The high rates of α-synuclein SAA positivity reported in patients with clinically diagnosed PSP, Alzheimer disease, Guam amyotrophic lateral sclerosis, and normal pressure hydrocephalus may relate to background copathology. Although reference laboratories have thus far shown a high degree of consistency, there can be variation in reporting from different laboratories. 7 A study examining α-synuclein SAAs in a common set of samples in 3 laboratories showed that assay results were inconsistent for 17% of patients with clinically diagnosed PD at baseline and for 13% of healthy controls at 3 years. There are therefore 3 possible interpretations of a positive α-synuclein SAA finding: (1) true positive with PD, meaning the patient has Lewy body PD and a positive α-synuclein SAA result; (2) true positive with -Abstract Truncated-

Quantitative Seed Amplification Assay: A Proof-of-Principle Study

α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward

Enhanced quantitation of pathological α-synuclein in patient biospecimens by RT-QuIC seed amplification assays

Α-Synuclein Seeding Amplification Assays for Diagnosing Synucleinopathies: an Innovative Tool in Clinical Implementation

Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson's disease

Real-time Determination of Aggregated Alpha-Synuclein Induced Membrane Disruption at Neuroblastoma Cells Using Scanning Ion Conductance Microscopy.

α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders

Ultrasensitive Detection of Aggregated Α-Synuclein Using Quiescent Seed Amplification Assay for the Diagnosis of Parkinson’s Disease

High-Yield α-Synuclein Purification and Ionic Strength Modification Pivotal to Seed Amplification Assay Performance and Reproducibility

A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson's disease

Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies

Diagnostic and prognostic value of alpha-synuclein seed amplification assay in Parkinson disease: a longitudinal cohort study

Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden

α-Synuclein seed amplification technology for Parkinson’s disease and related synucleinopathies

Limitations of α-Synuclein Seed Amplification Assay

CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders

Detection of α-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder

Evaluation of cerebrospinal fluid alpha-synuclein seed amplification assay in PSP and CBS

Evaluation of Cerebrospinal Fluid α‐Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome

Seed amplification assay results illustrate discrepancy in Parkinson’s disease clinical diagnostic accuracy and error rates